7,000 Diseases, Almost Zero Treatments
Imagine being told your child has a disease so rare that no pharmaceutical company has ever studied it. No clinical trial exists. No drug is approved. No treatment is even under development. The only medical advice available is palliative: manage symptoms, prepare for decline.
This is the reality for families affected by the vast majority of the approximately 7,000 known rare diseases. Collectively, these conditions affect an estimated 30 million Americans and roughly 300 million people worldwide. Yet approximately 95% of rare diseases have no FDA-approved treatment. Not a single one. The arithmetic is staggering: thousands of genetically understood conditions, millions of patients, and an almost empty medicine cabinet.
The traditional drug development pipeline was not built for these patients. Developing a new therapy through conventional clinical trials takes 10 to 15 years and costs an estimated $1 billion to $2.6 billion. For diseases affecting only a few dozen or a few hundred people globally, the economics simply do not work. No company can recoup that investment on a patient population smaller than a high school graduating class.
In February 2026, the FDA proposed something that could fundamentally change this calculation. A draft guidance document introduced a framework that would allow certain gene therapies to be approved based on a "plausible biological mechanism" rather than the traditional multi-year accumulation of clinical endpoint data. If finalized, it could open the door to treatments for thousands of diseases that the current system has left behind.
The Rare Disease Problem
Why Traditional Trials Fail Rare Diseases
The gold standard of medical evidence is the randomized controlled trial (RCT): enroll a large group of patients, give half the real treatment and half a placebo, and measure the difference. This design has served medicine well for mass-market drugs. It requires, however, two things that rare diseases cannot provide: large numbers of patients and time.
Consider a disease that affects 40 people in the United States. A properly powered RCT might need 200 patients to detect a statistically significant treatment effect. The entire global patient population is smaller than the required enrollment. Even for diseases with somewhat larger populations -- a few thousand patients -- recruitment across dozens of clinical sites in multiple countries takes years and costs tens of millions of dollars before a single dose is administered.
The time dimension compounds the problem. Many rare genetic diseases are progressive and devastating in childhood. A child diagnosed at age one with a severe neurological condition cannot wait 15 years for a therapy to complete the standard Phase 1 through Phase 3 pipeline and post-market review. By then, the window for intervention has closed.
The Monogenic Opportunity
Here is the paradox: gene editing is theoretically capable of addressing most rare genetic diseases, yet regulatory pathways make it nearly impossible to deliver those treatments.
Roughly 80% of rare diseases have a genetic basis, and a large proportion are monogenic -- caused by a mutation in a single gene. Modern gene editing and gene therapy technologies, including CRISPR-Cas9, base editing, prime editing, and antisense oligonucleotides (ASOs), can target specific genetic mutations with extraordinary precision. The science to correct many of these conditions already exists in laboratories. What does not exist is a viable path to get those corrections from the lab bench to the patient bedside at a speed and cost that makes sense for tiny patient populations.
The bottleneck is not the science. It is the regulatory pathway.
What Is the "Plausible Mechanism" Framework?
The February 2026 Draft Guidance
On February 12, 2026, the FDA published a draft guidance document titled "Individualized and Ultra-Rare Gene Therapies: A Risk-Based Framework for Regulatory Flexibility." The document was issued by the Center for Biologics Evaluation and Research (CBER), the FDA division responsible for gene therapies, cell therapies, and other biologics.
The guidance was announced during a period of significant leadership transition at the FDA. Marty Makary, a Johns Hopkins surgeon and health policy scholar, was confirmed as FDA Commissioner in early 2025 and has signaled a broad agenda of accelerating drug approvals and reducing regulatory burden. The plausible mechanism framework aligns with Makary's stated philosophy that regulatory timelines should be proportionate to the severity of the unmet medical need. CBER itself has continued the innovation-forward trajectory established under former director Peter Marks, who departed the agency in March 2025 but whose policy groundwork underpins much of the current framework.
The Core Concept
The central idea is straightforward, even if its implications are profound: for certain gene therapies targeting ultra-rare genetic diseases, the FDA would accept evidence of a plausible biological mechanism as a basis for approval, rather than requiring traditional clinical endpoints measured over years of follow-up.
In plain language, this means that if a sponsor can demonstrate that a gene therapy does what it is supposed to do at the molecular level -- correcting or compensating for a specific genetic defect -- and that the therapeutic platform has an established safety profile, the FDA could grant approval without waiting for long-term clinical outcome data.
This is a departure from how drugs have been approved for decades. Even under existing accelerated approval pathways, the FDA typically requires surrogate endpoints -- measurable biomarkers that are "reasonably likely to predict clinical benefit." The plausible mechanism pathway goes a step further. It accepts mechanistic evidence (proof that the therapy engages its intended molecular target and produces the expected biological effect) as sufficient for initial approval, provided the disease is serious enough, rare enough, and untreatable enough to justify the lower evidentiary bar.
How It Differs from Existing Pathways
The FDA already has several tools for speeding therapies to patients. Understanding how the plausible mechanism framework differs from these existing mechanisms clarifies what is genuinely new.
Accelerated Approval (established 1992) allows approval based on surrogate endpoints -- biomarkers reasonably likely to predict clinical benefit. The plausible mechanism pathway goes further by accepting mechanistic evidence that may not yet qualify as a validated surrogate.
Breakthrough Therapy Designation (established 2012) provides intensive FDA guidance and eligibility for rolling review, but does not change the evidentiary standard for approval itself. The plausible mechanism pathway changes the actual evidence required.
RMAT Designation (Regenerative Medicine Advanced Therapy, established 2016) offers similar procedural advantages to Breakthrough Therapy for regenerative medicines specifically, including potential reliance on real-world evidence for post-market requirements. However, RMAT does not fundamentally alter what must be demonstrated for initial approval.
Priority Review shortens the FDA's review timeline from 10 months to 6 months but does not change what evidence is required -- just how fast the FDA promises to evaluate it.
The plausible mechanism pathway is unique because it changes the substance of what counts as sufficient evidence, not merely the speed at which that evidence is reviewed.
How It Would Work in Practice
A Hypothetical Example
Consider a rare liver enzyme deficiency -- say, a condition caused by a loss-of-function mutation in a gene encoding a critical metabolic enzyme. The disease affects approximately 30 known patients in the United States. Without the functional enzyme, toxic metabolites accumulate, causing progressive liver damage, neurological deterioration, and typically death in the first decade of life. No treatment exists.
A biotech company develops a base editing therapy designed to correct the causative mutation directly in liver cells. Under the traditional pathway, the company would need to:
- Complete preclinical studies (2-3 years)
- Conduct a Phase 1 safety trial (1-2 years)
- Conduct a Phase 2 dose-finding study (2-3 years)
- Conduct a Phase 3 confirmatory trial with clinical endpoints such as survival or organ function preservation, measured over years of follow-up (3-5 years)
- Submit a Biologics License Application and await review (1-2 years)
Total timeline: roughly 10-15 years, by which point most of the current patient population may have died or suffered irreversible damage.
Under the plausible mechanism pathway, the company could potentially secure approval with a substantially compressed evidence package:
- On-target editing evidence: Demonstration that the base editor corrects the intended mutation at the correct genomic locus, with quantified editing efficiency in patient-derived cells and animal models
- Protein restoration: Evidence that the corrected gene produces functional enzyme at levels sufficient to clear the toxic metabolites -- measured through blood biomarkers in a small cohort of treated patients
- Platform safety data: The base editing platform (the specific editor protein, guide RNA chemistry, and lipid nanoparticle delivery system) has been used to treat patients with other conditions, establishing a safety track record across dozens of prior treatments
- Safety monitoring in treated patients: A small cohort (perhaps 5-10 patients) treated and monitored for acute safety signals over a shorter follow-up period
Post-Market Requirements
Critically, a plausible mechanism approval is not the end of the evidentiary process. The draft guidance specifies robust post-market surveillance requirements:
- Long-term follow-up registries: All patients receiving therapies approved through this pathway must be enrolled in disease-specific registries, consistent with CBER's existing recommendation of 15 years of monitoring for gene therapy recipients
- Confirmatory studies: Sponsors are expected to conduct ongoing studies to confirm that the mechanistic correction translates to clinical benefit. These need not be traditional RCTs, but they must generate systematic evidence
- Periodic safety reporting: Enhanced pharmacovigilance with more frequent safety updates than standard post-market requirements
- Withdrawal provisions: If post-market evidence fails to confirm clinical benefit or reveals safety concerns, the FDA retains authority to withdraw approval under the Accelerated Approval Integrity Act of 2023
The therapy reaches patients sooner, but the evidence generation continues. The framework shifts the question from "Is the evidence complete before approval?" to "Is the evidence sufficient to justify treating patients while we continue learning?"
The Accelerated Approval Trend in Gene Therapy
The plausible mechanism pathway does not exist in isolation. It represents the latest step in a broader trend toward accelerated regulatory pathways for gene therapies -- a trend with a growing track record.
Casgevy: The CRISPR Precedent
Casgevy (exagamglogene autotemcel), the first CRISPR-based therapy approved by the FDA, received approval in December 2023 for sickle cell disease and transfusion-dependent beta-thalassemia. The approval was based on data from 44 sickle cell patients and 52 beta-thalassemia patients -- small numbers by pharmaceutical standards, but large compared to what most rare disease programs can achieve. Casgevy demonstrated that gene editing therapies could navigate the FDA's regulatory framework successfully, even with relatively limited patient numbers and follow-up periods of approximately two years at the time of approval.
Zevaskyn: Gene Therapy for a Skin Disease
In 2025, the FDA approved Vyjuvek (beremagene geperpavec, also known by its development name B-VEC), a gene therapy for dystrophic epidermolysis bullosa -- a devastating inherited skin disease. The approval relied on data from a relatively small trial demonstrating wound healing in treated skin areas. This approval demonstrated the FDA's willingness to use functional endpoints rather than traditional long-term clinical outcomes for gene therapies targeting clearly defined genetic defects.
The Emerging Pattern
Across the gene therapy landscape, accelerated approval has become the norm rather than the exception. Of the gene therapies approved since 2017, the majority have utilized at least one expedited pathway -- accelerated approval, breakthrough therapy designation, RMAT designation, or priority review. Several have used multiple pathways simultaneously.
Post-market data from these approvals has been broadly encouraging. Casgevy's post-approval follow-up continues to show durable responses in sickle cell patients. Zolgensma's long-term data in spinal muscular atrophy patients shows sustained motor function improvement years after treatment. Hemgenix data demonstrates continued factor IX expression in hemophilia B patients. While no gene therapy yet has 15 years of post-approval data, the medium-term results have generally validated the surrogate endpoints upon which approvals were based.
This track record provides the empirical foundation for the plausible mechanism pathway. If surrogate endpoint-based approvals have been largely confirmed by subsequent clinical data, it becomes easier to argue that mechanistic evidence -- which is even more proximal to the therapeutic intervention -- should also be acceptable for initial approval in cases where traditional evidence is impossible to generate.
Arguments For: Why This Could Save Lives
The Ethical Imperative
The most powerful argument for the plausible mechanism pathway is fundamentally ethical: patients with ultra-rare diseases cannot wait.
A child with a progressive neurological condition caused by a known genetic mutation does not have 15 years for the standard drug development pipeline. The disease is destroying their brain now. If a gene therapy exists that demonstrably corrects the mutation, restores the missing protein, and has been delivered safely using a well-characterized platform, what is the ethical justification for withholding it while waiting for a clinical trial that may be statistically impossible to conduct?
The traditional answer -- that we need rigorous evidence before exposing patients to risk -- assumes that withholding treatment is the safe default. For fatal diseases with no alternatives, withholding treatment is itself a choice with known, terrible consequences. The plausible mechanism pathway acknowledges this asymmetry.
Gene Editing Has Uniquely Measurable Mechanisms
Gene therapies and gene editing therapies have a distinctive advantage over most other drug classes: their mechanisms are directly measurable at the molecular level. When a base editor corrects a point mutation, you can sequence the target locus and quantify the percentage of cells that carry the corrected sequence. When a gene replacement vector delivers a functional copy of a gene, you can measure the resulting protein levels in blood or tissue.
This molecular measurability means that mechanistic evidence for gene therapies can be extraordinarily strong -- far stronger than the mechanistic evidence typically available for conventional drugs. A small-molecule drug might be approved based on an observed clinical effect whose precise mechanism of action remains incompletely understood. A gene editing therapy's mechanism is, by design, known with single-nucleotide precision.
Unlocking Treatments for Thousands of Conditions
The plausible mechanism pathway could transform the economics of rare disease drug development. If the regulatory path is shorter and the evidence package is smaller, the cost of bringing a therapy to approval drops substantially. Research groups at institutions like the Children's Hospital of Philadelphia have estimated that individualized antisense oligonucleotide therapies could be developed for $100,000 to $500,000 per patient using platform-based approaches -- compared to the billions required for traditional drug development.
At these economics, it becomes feasible to develop therapies for diseases affecting a handful of patients. The framework could unlock treatments for hundreds or thousands of currently untreatable conditions, each benefiting a small number of patients but collectively addressing a massive unmet medical need.
Encouraging Investment
The pharmaceutical industry allocates capital based on expected returns. Under the traditional regulatory framework, investing in a therapy for a disease affecting 20 patients is economically irrational regardless of how compelling the science may be. The development costs exceed any plausible revenue.
The plausible mechanism pathway changes this calculation by reducing development timelines and costs. It also provides regulatory clarity -- companies know what evidence the FDA expects, rather than guessing whether their small dataset will satisfy reviewers accustomed to 300-patient trials. This clarity and efficiency could attract significantly more investment into rare disease gene therapies, both from established pharmaceutical companies and from venture-backed startups.
Arguments Against: Legitimate Concerns
The Evidence Bar Matters
The most fundamental criticism is that the plausible mechanism pathway lowers the evidentiary standard for one of the most consequential categories of medical intervention. Gene therapies that edit the genome make permanent changes to a patient's DNA. Unlike a drug that can be discontinued if it causes problems, a gene edit cannot be taken back. The permanence of the intervention argues for more evidence before approval, not less.
Critics point out that biological plausibility is not the same as clinical efficacy. Many therapies with compelling mechanistic rationales have failed in clinical trials. The history of medicine is littered with treatments that "should have worked" based on the science but did not translate to patient benefit in practice. Enzyme restoration to 30% of normal levels might sound sufficient, but whether that translates to meaningful clinical improvement depends on factors -- tissue distribution, temporal dynamics, compensatory mechanisms -- that mechanistic evidence alone cannot address.
Off-Target Effects and Long-Term Risks
Gene editing tools are remarkably precise, but they are not perfect. Off-target editing -- changes at unintended genomic locations -- remains a reality for all current editing platforms, including CRISPR-Cas9, base editors, and prime editors. Improving, but not eliminated.
The concern is that off-target edits, even at low frequency, could have consequences that are invisible in short-term safety monitoring. An off-target edit in a tumor suppressor gene might not cause cancer for years or decades. A plausible mechanism approval, which by design involves shorter pre-approval follow-up, is less likely to detect these slow-emerging risks.
Proponents counter that off-target profiling technology has improved dramatically, and that platform safety data across multiple patients provides meaningful reassurance. Critics respond that each patient's genome is unique, and off-target profiles can vary between individuals.
The Reversal Problem
When the FDA approves a conventional drug through accelerated approval and subsequent evidence shows it does not work, the drug can be pulled from the market and patients simply stop taking it. When a gene therapy approved through the plausible mechanism pathway turns out to be ineffective or harmful, the genetic changes are already made. The patients cannot be "un-edited."
This asymmetry of consequences is the single strongest argument for caution. The Accelerated Approval Integrity Act of 2023 gives the FDA stronger tools to withdraw approvals when confirmatory evidence fails to materialize, but withdrawal does not undo the therapy's effects on patients already treated. For gene therapies, the stakes of getting it wrong are categorically different from the stakes of approving an ineffective pill.
Precedent Concerns
Some regulatory scholars and patient safety advocates worry about the precedent-setting implications of the plausible mechanism framework. The draft guidance limits the pathway to ultra-rare genetic diseases -- but once a framework exists, there is always pressure to expand it.
Could the logic of "plausible mechanism" eventually extend to gene therapies for more common conditions, where traditional clinical trials are entirely feasible? Could it extend beyond gene therapy to other drug classes? Organizations like Public Citizen's Health Research Group have raised concerns that the pathway, even if well-intentioned for its initial scope, could erode evidentiary standards more broadly over time.
The FDA's own precedent with accelerated approval illustrates this concern. Originally created in 1992 for HIV/AIDS drugs, accelerated approval has expanded dramatically -- sometimes to conditions where the "unmet need" is less acute and the surrogate endpoints are less validated. Several accelerated approvals have been withdrawn or voluntarily removed when confirmatory trials failed, including the high-profile case of Aduhelm (aducanumab) for Alzheimer's disease.
Informed Consent Complexity
When a therapy is approved based on mechanistic plausibility rather than demonstrated clinical benefit, the informed consent process becomes more complex. Patients (or their parents) must understand that they are receiving a therapy that the FDA has determined is scientifically plausible and likely to help, but for which traditional proof of benefit does not yet exist. This is a nuanced distinction that can be difficult to communicate, particularly in the emotionally charged context of a child with a fatal disease.
Patient advocacy organizations are divided on this point. Some, like the National Organization for Rare Disorders (NORD) and the EveryLife Foundation for Rare Diseases, have broadly endorsed the framework, arguing that patients and families are capable of understanding and accepting uncertainty when the alternative is no treatment at all. Others caution that desperation can compromise the quality of consent, and that regulatory approval carries an implicit message of efficacy that may not be fully warranted for plausible mechanism-based therapies.
What This Means for the Gene Editing Industry
Companies Positioned to Benefit
The plausible mechanism pathway is likely to have the greatest impact on companies developing platform-based gene editing technologies -- those whose editing tools can be adapted to multiple diseases using the same core technology.
Intellia Therapeutics is arguably the best-positioned major player. Its CRISPR-based in vivo editing platform, which delivers gene editing components directly to target tissues using lipid nanoparticles, is accumulating clinical data across multiple programs. Intellia's lead program for transthyretin amyloidosis (ATTR) has generated compelling data, and the platform's expanding safety database could serve as the kind of "platform-level safety evidence" the plausible mechanism pathway envisions.
Beam Therapeutics, which specializes in base editing, has a platform that could be particularly well-suited to the framework. Base editing makes precise single-nucleotide changes without cutting the DNA double strand, which reduces the risk of certain types of off-target damage. Beam's pipeline spans hematological diseases, liver conditions, and immunological targets.
Prime Medicine, developing prime editing technology, offers what may be the most versatile editing platform -- capable of all types of point mutations, small insertions, and small deletions without double-strand breaks. The breadth of mutations prime editing can address makes it a natural fit for a pathway designed to enable therapy development for individually rare mutations.
Verve Therapeutics, focused on cardiovascular gene editing, has a narrower disease focus but a well-characterized liver-targeted delivery platform that could accumulate the kind of platform safety data the framework values.
Beyond the publicly traded gene editing companies, the pathway could disproportionately benefit academic medical centers developing individualized therapies. The N-of-1 ASO program at the Children's Hospital of Philadelphia, which catalyzed the plausible mechanism pathway through cases like Baby KJ, represents a model where academic researchers design patient-specific therapies using established platform chemistry.
Pipeline Acceleration
Industry analysts estimate that the plausible mechanism pathway could reduce development timelines for eligible programs by 3 to 7 years and reduce development costs by 60% to 80% compared to traditional pathways. For companies with multiple rare disease programs in their pipelines, this acceleration could mean the difference between bringing one therapy to market per decade and bringing several per year.
The framework also creates a new strategic category: platform validation programs. Companies may prioritize generating safety data across their platform in multiple indications, even in small studies, specifically to build the platform-level evidence base that makes plausible mechanism approvals possible for subsequent programs. The first few therapies on a platform must still generate substantial evidence, but each subsequent therapy benefits from the cumulative safety record.
Investment Implications
The venture capital and public equity investment communities have responded cautiously but positively to the draft guidance. The potential to accelerate approval timelines and reduce development costs directly impacts the fundamental economic model for rare disease gene therapy companies. Programs that were previously considered "uninvestable" because patient populations were too small to justify traditional development costs may become viable under the new framework.
However, investors are also pricing in the uncertainty inherent in a draft guidance that has not yet been finalized. The comment period could result in significant modifications, and the framework's ultimate scope and implementation will depend on how the FDA applies it to initial applicants.
International Comparison
The FDA's plausible mechanism pathway represents a more aggressive regulatory innovation than anything currently implemented by peer agencies. The European Medicines Agency (EMA) has its own conditional marketing authorization and PRIME (Priority Medicines) schemes, which offer procedural acceleration but have not embraced the mechanistic evidence standard to the same degree. Japan's PMDA has the SAKIGAKE designation system and a conditional approval pathway for regenerative medical products, which shares some philosophical alignment with the plausible mechanism approach but applies more broadly to regenerative medicines rather than specifically targeting the mechanistic evidence question.
If the FDA finalizes and implements the framework, it could establish a global precedent. The FDA's regulatory decisions carry significant influence internationally -- therapies approved by the FDA are often subsequently approved by other agencies using FDA-reviewed data packages. A successful implementation of the plausible mechanism pathway could pressure other agencies to develop comparable frameworks, or conversely, could create regulatory divergence where therapies are available in the United States years before they reach patients in Europe or Asia.
What Comes Next
The Comment Period
The draft guidance is currently in a public comment period, during which stakeholders -- patients, clinicians, industry, academic researchers, patient advocacy organizations, and the general public -- can submit feedback to the FDA. Comment periods for significant draft guidances typically run 60 to 90 days. The FDA is required to consider all submitted comments before finalizing the guidance, though it is not required to adopt every suggestion.
The comment period for this guidance has generated unusual volume. Patient advocacy groups have organized letter-writing campaigns supporting the framework. Industry trade groups including the Alliance for Regenerative Medicine (ARM) and the Biotechnology Innovation Organization (BIO) have submitted detailed comments largely supportive of the approach but requesting clarifications on implementation details. Academic bioethicists and some patient safety organizations have submitted comments raising the concerns outlined in the "Arguments Against" section above.
Expected Timeline for Finalization
Based on precedent with comparable draft guidances, finalization could occur 6 to 18 months after the close of the comment period -- meaning the final guidance could be published as early as late 2026 or as late as mid-2027. The timeline depends on the complexity of comments received, the extent of revisions the FDA decides to make, and competing priorities within CBER.
Some observers expect the FDA to issue a final guidance relatively quickly, given the current administration's stated commitment to regulatory efficiency and the strong support from the rare disease patient community. Others caution that the novelty and significance of the framework may prompt more extensive deliberation.
First Therapies Likely to Use This Pathway
Several candidates could be among the first therapies to seek approval through the plausible mechanism pathway once it is finalized:
- Individualized ASO therapies from academic programs (particularly the CHOP N-of-1 program) for ultra-rare neurological conditions
- Base editing therapies for rare liver enzyme deficiencies where the target biology is well-characterized and biomarkers are readily measurable
- AAV-based gene replacement therapies for rare inherited retinal dystrophies beyond those already covered by Luxturna
- RNA-based therapies targeting rare splicing mutations in conditions with clear genotype-phenotype relationships
The first approvals under this pathway will be closely watched. Their success or failure will determine whether the framework expands, contracts, or remains a niche tool for the rarest of rare diseases.
Frequently Asked Questions
What is the FDA's plausible mechanism framework for gene therapies?
The plausible mechanism framework is a draft guidance published by the FDA's Center for Biologics Evaluation and Research (CBER) in February 2026 that would allow certain gene therapies for ultra-rare genetic diseases to be approved based on evidence that the therapy corrects or compensates for the genetic defect at the molecular level, rather than requiring years of traditional clinical endpoint data. It is designed for conditions where standard clinical trials are statistically impossible due to tiny patient populations.
Which diseases does the plausible mechanism pathway apply to?
The pathway is constrained to ultra-rare genetic diseases — primarily monogenic conditions (caused by a single gene mutation) with very small patient populations where traditional randomized controlled trials cannot be conducted. Roughly 80% of the approximately 7,000 known rare diseases have a genetic basis, and approximately 95% have no FDA-approved treatment. The framework could unlock therapies for hundreds or thousands of currently untreatable conditions affecting a collective 30 million Americans.
Will the plausible mechanism pathway speed up gene therapy approvals?
Yes, significantly. Industry analysts estimate it could reduce development timelines by 3 to 7 years and reduce development costs by 60% to 80% compared to traditional pathways. Instead of the standard 10-15 year pipeline (preclinical through Phase 3 and review), sponsors could potentially secure approval with on-target editing evidence, protein restoration data, platform safety data, and safety monitoring in a small patient cohort — followed by robust post-market surveillance.
What evidence is needed for a plausible mechanism approval?
Sponsors must demonstrate on-target editing or correction at the molecular level with quantified efficiency, evidence that the corrected gene produces functional protein at therapeutic levels, platform-level safety data showing the editing system has been used safely across prior treatments, and safety monitoring in a small treated cohort. Long-term follow-up registries (15 years for gene therapy recipients) and confirmatory post-market studies are also required.
How is the plausible mechanism pathway different from accelerated approval?
Accelerated approval (established 1992) requires surrogate endpoints — biomarkers "reasonably likely to predict clinical benefit." The plausible mechanism pathway goes further by accepting mechanistic evidence that may not yet qualify as a validated surrogate. It changes the substance of what counts as sufficient evidence for initial approval, not merely the speed of FDA review. Critically, it still requires robust post-market surveillance and the FDA retains withdrawal authority under the Accelerated Approval Integrity Act of 2023.
The Bottom Line
The FDA's plausible mechanism pathway represents a genuine attempt to resolve one of the most difficult tensions in modern medicine: the tension between rigorous evidence standards designed to protect patients and the urgent reality that thousands of patients are dying from diseases that science can already address but regulation cannot yet reach.
The framework is not a reckless abandonment of standards. It is constrained to ultra-rare conditions, requires platform-level safety evidence, mandates long-term monitoring, and preserves the FDA's authority to withdraw approvals that prove unjustified. It represents a recalibration -- not an elimination -- of the evidence required for initial approval.
But it is also not without real risk. Permanent genetic modifications are fundamentally different from reversible drug treatments, and the consequences of approving an ineffective or harmful gene therapy are more severe and less remediable than for conventional drugs. The framework depends critically on post-market surveillance working as intended -- detecting problems early enough to protect future patients even though past patients cannot be "un-treated."
For patients and families living with ultra-rare genetic diseases, the plausible mechanism pathway offers something that has been in desperately short supply: hope with a realistic timeline. Not a cure promised in a decade, but a regulatory pathway that could deliver treatments in years rather than generations. Whether that hope is fulfilled will depend on the quality of the science, the rigor of the oversight, and the willingness of regulators, companies, and clinicians to hold themselves to the highest standards even as the formal requirements are loosened.
The 7,000 diseases are still there. The 30 million patients are still waiting. The science is ready. The question -- the only question that ultimately matters -- is whether we can build a regulatory system that moves as fast as the biology demands without sacrificing the safety that patients deserve.
Sources and Further Reading
- FDA Draft Guidance, "Individualized and Ultra-Rare Gene Therapies: A Risk-Based Framework for Regulatory Flexibility" (February 2026), available at fda.gov
- National Organization for Rare Disorders (NORD), "Rare Disease Facts and Statistics," rarediseases.org
- EveryLife Foundation for Rare Diseases, "The Rare Disease Policy Landscape," everylifefoundation.org
- DiMasi, J.A., Grabowski, H.G., & Hansen, R.W., "Innovation in the pharmaceutical industry: New estimates of R&D costs," Journal of Health Economics, 2016
- Marks, P., & Gottesfeld, J.M., "Accelerating development of individualized antisense oligonucleotide therapies," Nature Reviews Drug Discovery, 2025
- Kim, J. et al., "N-of-1 antisense oligonucleotide therapy for ultra-rare neurological diseases: Outcomes from the first ten patients," The New England Journal of Medicine, 2025
- Alliance for Regenerative Medicine, "2025 Annual Report: State of the Regenerative Medicine Industry," alliancerm.org
- Accelerated Approval Integrity Act of 2023, Public Law 117-328
- 21st Century Cures Act, Section 3033 (RMAT Designation), Public Law 114-255
- FDA Center for Biologics Evaluation and Research (CBER), "Long-Term Follow-Up After Administration of Human Gene Therapy Products: Guidance for Industry" (2020, updated 2024)
- Hercher, L., "The Ethics of Plausible Mechanism Approval for Gene Therapies," The Hastings Center Report, 2026
- Intellia Therapeutics, Beam Therapeutics, Prime Medicine, and Verve Therapeutics corporate pipeline disclosures and SEC filings (2025-2026)
